Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
This trial is conducted in Europe. The aim of this trial is to assess whether increasing
 doses of somatropin (Norditropin®) can maintain the initial increase in height velocity and
 improve final height. This trial has two trial periods, a main period of 4 years and an
 extension period until final height is reached.
Inclusion Criteria:

 -  Turner Syndrome

 -  Well documented growth rate during the previous year

 -  Height below the 50th percentile for the age in Dutch children

 -  Normal thyroid function

 Exclusion Criteria:

 -  Any endocrine or metabolic disorder

 -  Growth failure due to disorders of genitourinary, cardio-pulmonary, gastro-intestinal
 and nervous systems, nutritional/vitamins deficiencies and chondrodysplasias

 -  Patients with hydrocephalus